Allergic Rhinitis. Other diseases of upper respiratory tract
Conditions
Interventions
Intervention 1: Intervention group uses Origanum Vulgaris L. Extract
nasal spray, 40g/20ml, 2 puff, 3 times/day, for 1 month. Intervention 2: Control group uses placebo for 1 month.
Treatment - Drugs
Placebo
Intervention group uses Origanum Vulgaris L. Extract
nasal spray, 40g/20ml, 2 puff, 3 times/day, for 1 month.
Control group uses placebo for 1 month.
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: men and women aged 18 to 60 years old; outpatients with a history or diagnosis of allergic rhinitis for at least 6 months before the first visit; allergic rhinitis and the numbers of eosinophil in the nasal mucous or the skin Prick test is proven (if not already done during the last 6 months); signing informed consent; patients with a diagnosis of allergic rhinitis are previous topical or systemic treatments include antihistamines and corticosteroids have not responded or those with complications who have had previous with these drugs, do not want or cannot be treated with these drugs are; no anatomical abnormalities in the nose (nasal polyp or severe deviation); drugs that are used to treat allergies and if they use, it must be discontinued before the study; patients who are able to read and understand the consent form; ; patients who have not dementia; are not pregnant or are able to communicate and patients without nasopharyngeal tumors; patients who have not a history of drug allergy with Origanum vulgare. Exclusion criteria: patients taking drugs other than drugs that must consume according to the research plan, the duration of the project will be excluded from use; patients during the study have a fungal, viral or bacterial disease; patients who do not follow the recommended instructions will be excluded.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The overall clinical symptoms. Timepoint: Before the intervention and after intervention once a week, for a month. Method of measurement: Rhinitis Quality of Life Questionnaire.;Severity of rhinorrhea. Timepoint: Before the intervention and after intervention once a week, for a month. Method of measurement: Rhinitis Quality of Life Questionnaire.;Severity of itchy nose. Timepoint: Before the intervention and after intervention once a week, for a month. Method of measurement: Rhinitis Quality of Life Questionnaire.;Severity of nasal obstruction. Timepoint: Before the intervention and after intervention once a week, for a month. Method of measurement: Rhinitis Quality of Life Questionnaire.;Frequency of sneezing per day. Timepoint: Before the intervention and after intervention once a week, for a month. Method of measurement: Rhinitis Quality of Life Questionnaire.;Severity of itchy palate. Timepoint: Before the intervention and after intervention once a week, for a month. Method of measurement: Rhinitis Quality of Life Questionnaire.;Severity of eye symptoms. Timepoint: Before the intervention and after intervention once a week, for a month. Method of measurement: Rhinitis Quality of Life Questionnaire.;Number of nose palate eosinophils. Timepoint: Before the intervention and after intervention once a week, for a month. Method of measurement: Rhinitis Quality of Life Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of allergic rhinitis symptoms recovery based on the international diagnostic criteria of rhinitis quality of life questionnaire. Timepoint: Before the intervention and after intervention once a week, for a month. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyed Morteza Emami Alorizi
Shiraz University of Medical Sciences
Outcome results
None listed